#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Endo International to acquire Somerset Therapeutics

Share on Twitter Share on LinkedIn
Staff Writer | April 27, 2018
Endo International announced that it has reached definitive agreements to acquire Somerset Therapeutics.
Acquisition   A New Jersey based specialty pharmaceutical company
Somerset Therapeutics is a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and the business of its India based affiliate Wintac Limited, which operates as Somerset Therapeutics' contract developer and manufacturer.

Endo is paying approximately $190 million in total for Somerset Therapeutics and Wintac's business.

Together, the acquisitions will secure for Endo's Par Sterile injectable business Somerset Therapeutics' commercial and pipeline products as well as Wintac's manufacturing capabilities for those products.

Focusing on the fast-growing U.S. sterile injectable drugs market, Somerset Therapeutics' portfolio includes 8 commercial products as well as a pipeline of more than 40 products, over 25 of which have been submitted for approval to the U.S. Food and Drug Administration (FDA).

With this acquisition, Endo significantly increases the number of filed injectable applications.

Wintac, located in Bangalore, India, operates an FDA-inspected sterile manufacturing facility with proven sterile injectable and ophthalmic R&D capabilities.